-
1.发明公开
公开(公告)号：EP3604302A1
公开(公告)日：2020-02-05
申请号：EP19175566.9
申请日：2011-05-17
发明人： OLIVER-SHAFFER, Patricia , SHAPIRO, Gideon , CHESWORTH, Richard , KISHIDA, Muneki , ISHIGE, Takayuki
IPC分类号： C07D453/02 , A61K31/439 , A61P25/00
摘要： Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.
-
2.发明授权Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof 有权用（R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺及其药学上可接受的盐治疗精神分裂症的阴性症状
公开(公告)号：EP2889033B1
公开(公告)日：2018-03-21
申请号：EP15151165.6
申请日：2009-11-19
IPC分类号： A61K31/439 , A61P25/00
CPC分类号： A61K31/439 , A61P25/00
摘要： (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have precognitive effects in humans at unexpectedly low doses. Thus, (R) -7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.
-
公开(公告)号：EP2297133B1
公开(公告)日：2017-09-13
申请号：EP09770926.5
申请日：2009-06-24
发明人： RIPKA, Amy , SHAPIRO, Gideon , CHESWORTH, Richard
IPC分类号： C07D401/12 , C07D401/14 , C07D405/12 , C07D413/14 , C07D417/14 , A61K31/4409 , A61K31/5355 , A61P25/18
CPC分类号： A61K31/53 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/517 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
-
公开(公告)号：EP2970245A1
公开(公告)日：2016-01-20
申请号：EP14767356.0
申请日：2014-03-14
发明人： OLIVER, Patricia
IPC分类号： C07D413/14 , G01N23/207
CPC分类号： C07D487/04 , C07B2200/13
摘要： Disclosed are novel crystalline polymorphic forms of 4-(4-(imidazo[l,2-b]pyridazin- 2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one and salts thereof, methods of preparing the crystalline polymorphic forms and salts thereof, pharmaceutical compositions comprising the crystalline polymorphic forms and salts thereof, and methods of treating CNS disorders, eating disorders, obesity, compulsive gambling, sexual disorders, narcolepsy, sleep disorders, diabetes, metabolic syndrome, schizophrenia, schizo-affective conditions, Huntington's disease, bipolar disorders, dystonic conditions and tardive dyskinesia, or for use in smoking cessation treatment in a patient using the crystalline polymorphic forms and salts thereof.
-
公开(公告)号：EP2617420B1
公开(公告)日：2015-09-23
申请号：EP13150322.9
申请日：2009-12-18
发明人： Shapiro, Gideon , Ripka, Amy , Chesworth, Richard
IPC分类号： A61K31/4985 , A61P25/18
CPC分类号： C07D487/04 , C07D405/04 , C07D471/04
-
6.发明授权Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof 有权认知障碍的治疗（R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺和它的药学上可接受的盐
公开(公告)号：EP2540297B1
公开(公告)日：2015-04-08
申请号：EP12185913.6
申请日：2009-11-19
IPC分类号： A61K31/439 , A61P25/00
CPC分类号： A61K31/439 , A61P25/00
摘要： (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have precognitive effects in humans at unexpectedly low doses. Thus, (R) -7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.
-
公开(公告)号：EP2846796A1
公开(公告)日：2015-03-18
申请号：EP13787744.5
申请日：2013-05-06
发明人： KOENIG, Gerhard , HILT, Dana, C.
IPC分类号： A61K31/439
CPC分类号： A61K31/439 , A61K31/55
摘要： A method of administering an effective amount of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. One embodiment of the invention provides a method of maintaining, treating, curing and/or improving at least one cognitive function in a patient in need thereof, comprising: administering to the patient, for an extended period, an effective dose of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：EP2970245A4
公开(公告)日：2016-10-19
申请号：EP14767356
申请日：2014-03-14
发明人： OLIVER PATRICIA
IPC分类号： C07D487/04 , A61K31/4985 , A61P25/18
CPC分类号： C07D487/04 , C07B2200/13
-
9.发明公开Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof 有权与（R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺和药学上可接受的盐精神分裂症的阴性症状的治疗
公开(公告)号：EP2889033A1
公开(公告)日：2015-07-01
申请号：EP15151165.6
申请日：2009-11-19
IPC分类号： A61K31/439 , A61P25/00
CPC分类号： A61K31/439 , A61P25/00
摘要： (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have precognitive effects in humans at unexpectedly low doses. Thus, (R) -7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.
摘要翻译： （R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺已被发现具有在出乎意料低的剂量在人类中预知的影响。 因此，（R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-羧酰胺和其可药用盐可以在出乎意料低的剂量使用改善认知。
-
公开(公告)号：EP3272748A1
公开(公告)日：2018-01-24
申请号：EP17186513.2
申请日：2011-05-17
发明人： OLIVER-SHAFFER, Patricia , SHAPIRO, Gideon , CHESWORTH, Richard , KISHIDA, Muneki , ISHIGE, Takayuki
IPC分类号： C07D453/02 , A61K31/439 , A61P25/00
CPC分类号： C07D453/02 , A61K9/4833 , A61K31/439 , C07B2200/13 , C30B29/54
摘要： Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.023 秒)
